Online Only Articles

GA101 P329GLALA, a variant of obinutuzumab with abolished ADCC, ADCP and CDC function but retained cell death induction, is as efficient as rituximab in B-cell depletion and antitumor activity

Roche Pharmaceutical Research & Early Development, 1Roche Innovation Center Zurich, Switzerland
Roche Innovation Center Munich, Germany
Roche Innovation Center Munich, Germany
Roche Pharmaceutical Research & Early Development, 1Roche Innovation Center Zurich, Switzerland
Roche Innovation Center Munich, Germany
Roche Pharmaceutical Research & Early Development, 1Roche Innovation Center Zurich, Switzerland
Roche Innovation Center Basel, Switzerland
Roche Pharmaceutical Research & Early Development, 1Roche Innovation Center Zurich, Switzerland
Roche Pharmaceutical Research & Early Development, 1Roche Innovation Center Zurich, Switzerland
Roche Pharmaceutical Research & Early Development, 1Roche Innovation Center Zurich, Switzerland
Roche Pharmaceutical Research & Early Development, 1Roche Innovation Center Zurich, Switzerland
Roche Pharmaceutical Research & Early Development, 1Roche Innovation Center Zurich, Switzerland
Vol. 103 No. 2 (2018): February, 2018 https://doi.org/10.3324/haematol.2017.178996